Assetmark Inc. Buys 23,988 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Assetmark Inc. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.1% during the second quarter, Holdings Channel reports. The fund owned 127,621 shares of the biopharmaceutical company’s stock after acquiring an additional 23,988 shares during the period. Assetmark Inc.’s holdings in Regeneron Pharmaceuticals were worth $67,001,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Activest Wealth Management grew its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. Finally, Colonial Trust Advisors bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $652.91 on Thursday. The company has a market capitalization of $69.20 billion, a price-to-earnings ratio of 15.63, a P/E/G ratio of 2.04 and a beta of 0.31. The firm’s 50 day simple moving average is $579.44 and its 200 day simple moving average is $564.03. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.82 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $935.86.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the company posted $12.46 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. Bank of America raised their target price on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research note on Wednesday. Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, October 23rd. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $813.78.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.